Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Head-to-head comparison of Adipotide and Cagrilintide — mechanism, dosing, side effects, legal status, and pricing.
Adipotide (FTPP) is a chimeric peptidomimetic developed in the Arap/Pasqualini lab (originally at MD Anderson) that couples a 9-residue homing motif (CKGGRAKDC) — isolated by in vivo phage display as a ligand for prohibitin on white-adipose-tissue vasculature — to the D-amino-acid pro-apoptotic domain D(KLAKLAK)2. It is an experimental research compound, NOT FDA-approved for any indication. A clinical-development program in prostate-cancer-associated obesity reached early-phase testing and was ultimately discontinued.
Cagrilintide is a long-acting acylated amylin analog developed by Novo Nordisk. It is investigational and not FDA-approved; Novo Nordisk's lead development path is the CagriSema co-formulation with semaglutide for weight management. Monotherapy cagrilintide was evaluated in Phase 2 but was deprioritized in favor of the combination.
Adipotide
Cagrilintide
Category
Legal Status
Mechanism
Dose Range
Route
COA-verified vendors · trust score ≥70 required · single-vial price — bulk/bundle deals may be lower
Adipotide
Cagrilintide
COA corpus from Disclosed Labs — independently tested batches only.
Adipotide
2
COAs
98.8%
Avg purity
2
Labs
Cagrilintide
79
COAs
99.7%
Avg purity
13
Labs
Foundational proof-of-concept in obese mice (Kolonin et al., Nat Med 2004, PMID 15133506). A 4-week dosing study in spontaneously obese rhesus macaques showed substantial body-weight and fat-mass loss and improved insulin sensitivity but produced dose-dependent renal proximal-tubule toxicity (Barnhart et al., Sci Transl Med 2011, PMID 22072637). A small Phase 1 trial in obese prostate-cancer patients was initiated and later terminated; the program was permanently discontinued. No published human efficacy data. Grey-market human use is unstudied and carries documented nephrotoxicity risk.
A Phase 2 dose-finding trial of cagrilintide monotherapy demonstrated dose-dependent weight loss of up to 10.8% over 26 weeks versus 3.0% for placebo (Lau et al., The Lancet, 2021). Novo Nordisk pivoted development to the CagriSema co-formulation with semaglutide 2.4 mg. The Phase 3 REDEFINE 1 trial (n=3,417, 68 weeks) in obesity reported ~22.7% mean body weight reduction on the treatment-policy estimand, with 91.9% achieving ≥5% weight loss versus 31.5% for placebo. Novo Nordisk submitted a CagriSema NDA to the FDA in December 2025; the application is under review in 2026. Cagrilintide is not FDA-approved as a standalone therapy, and CagriSema is not yet approved as of April 2026.
Key references
Adipotide and Cagrilintide are both in the Metabolic category and may have overlapping mechanisms. Researchers should review both profiles carefully, understand the mechanisms of action, and monitor the relevant biomarkers when combining compounds in the same class. As always, consult a licensed healthcare provider before making any decisions about combining research compounds.
This platform provides informational tools only, not medical advice. This comparison is for educational purposes only. Consult a licensed provider.
Frequency
Dosing Notes
Side Effects
Contraindications
Lab Testing
Disclosed Labs